Why Revolution Medicines, Inc. (RVMD) Stock Fell 6.3% on Oct 8, 2026
What happened
Revolution Medicines fell 6.19% to $188.43 as investors engaged in profit-taking on high-flying biotech stocks amid technical weakness and recent insider selling disclosures, according to web sources tracking the October 8 session. The decline occurred despite the company's announcement of patient enrollment in its Phase 3 RASolute 309 trial for metastatic pancreatic cancer, suggesting the positive operational update was overshadowed by sector-wide valuation digestion following a sustained multi-month rally.
RVMD earnings on November 4, 2026 (consensus EPS estimate: –$2.35); monitor for any updates on RASolute 309 enrollment pace and management commentary on insider transactions.
Frequently asked questions
Why did Revolution Medicines, Inc. (RVMD) stock fall on Oct 8, 2026?
Revolution Medicines fell 6.19% to $188.43 as investors engaged in profit-taking on high-flying biotech stocks amid technical weakness and recent insider selling disclosures, according to web sources tracking the October 8 session. The decline occurred despite the company's announcement of patient enrollment in its Phase 3 RASolute 309 trial for metastatic pancreatic cancer, suggesting the positive operational update was overshadowed by sector-wide valuation digestion following a sustained multi-month rally.
How much did RVMD stock fall on Oct 8, 2026?
RVMD fell 6.3% during the Oct 8, 2026 trading session.